<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406729</url>
  </required_header>
  <id_info>
    <org_study_id>DEN-03-IB</org_study_id>
    <secondary_id>U1111-1168-8679</secondary_id>
    <nct_id>NCT02406729</nct_id>
  </id_info>
  <brief_title>Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine</brief_title>
  <official_title>Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will
      evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine
      produced by Butantan Institute.

      The study will be carried out in multiple sites in Brazil. The study will be community-based
      in select urban areas where there's dengue transmission.

      Study's intervention will be a single dose of the tetravalent dengue vaccine or placebo in a
      ratio 2:1. For efficacy analysis will be considered all dengue cases occurring after 28 days
      post-vaccination in the entire population of 16944 participants.

      For safety analysis participants will be divided in three age groups: 18 to 59 ys, 7-17 ys
      and 2 to 6 ys. In each of these age groups there will be a minimum of 4992 participants. The
      age groups of 18 to 59 ys and 7 to 17 ys will start first. Once safety data for the first 21
      days after vaccination is analysed for 450 participants in 7-to17-ys age group, the following
      group, of 2 to 6 ys, will start.

      The study's hypothesis is that the vaccine under investigation and produced by Butantan
      Institute is safe and provides protection against dengue symptomatic disease of 80% or more
      with a lower bound of the 95% confidence interval of 25%. This way, the expected number of
      dengue cases virologically confirmed is 24 or more which will provide a response in terms of
      vaccine efficacy.

      All participants will be followed up for five years to verify dengue incidence, regardless
      severity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (incidence density of symptomatic dengue cases, virologically confirmed)</measure>
    <time_frame>at 52 weeks post vaccination, all cases after 28 days post-vaccination</time_frame>
    <description>• The primary efficacy outcome is incidence density of symptomatic dengue cases, virologically confirmed, after 28 days post-vaccination. Virological confirmation might be done by viral isolation, RT-PCR and/or detection of NS1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (adverse reactions)</measure>
    <time_frame>in the first 21 days post-vaccination</time_frame>
    <description>• The primary safety outcome is the frequency of local and systemic adverse reactions, solicited and non-solicited in the three age groups, within the first 21 days post-vaccination. Adverse reactions are defined as adverse events that have a reasonable causal relationship with vaccination.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16944</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Dengue 1,2,3,4 (attenuated) vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Single dose, SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dengue 1,2,3,4 (attenuated) vaccine</intervention_name>
    <description>Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous</description>
    <arm_group_label>Dengue 1,2,3,4 (attenuated) vaccine</arm_group_label>
    <other_name>Butantan DV</other_name>
    <other_name>TetraVax-DV-TV003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Route:subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children who have completed 24 months of age, adolescents and adults who have not
             completed 60 years of age;

          2. Agree with periodic contacts, either/or by phone, electronic means, and home visits.

          3. Show voluntary intention to participate in the study, documented by the participant's
             or participant's legal representative's signature of the informed consent form.

        Exclusion Criteria:

          1. For women: Pregnancy (confirmed by positive beta-hCG test) or breastfeeding;

          2. Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as per
             clinical history and/or physical examination;

          3. Compromised immune system diseases including: decompensated diabetes mellitus, cancer
             (except basal cell carcinoma), congenital or acquired immune deficiencies and not
             controlled autoimmune, as per clinical history and/or physical examination;

          4. Behavioral, cognitive or psychiatric disease that in the opinion of the principal
             investigator or his representative physician, affects the participant ability to
             understand and cooperate with all study protocol requirements;

          5. Abusive usage of alcohol or drugs in the past 12 months that has caused medical,
             professional or family problems, indicated by clinical history;

          6. History of severe allergic reactions or anaphylaxis to the vaccine or to components of
             the vaccine in study;

          7. History of asplenia;

          8. Use of any investigational product within 28 days before or after receiving this study
             vaccination;

          9. Has participated in another clinical trial six months prior to inclusion in the study
             or planning to participate in another clinical trial within 2 years following
             inclusion;

         10. Use of immunosuppressant drugs such as: antineoplastic chemotherapy, radiation
             therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids
             use (except topical or nasal). For this protocol will be considered for exclusion use
             of corticosteroids 3 months prior to the inclusion in the study and 6 months prior to
             the inclusion for the other therapies mentioned, and planned use of any
             immunosuppressant therapy within 2 years following inclusion in the study. It will be
             considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥20 mg
             of prednisone per day for adults and the equivalent of prednisone at 2 mg/kg/day for
             children for over 7 days;

         11. Have received blood products in the past three months, including transfusions or
             immunoglobulin, or scheduled administration of blood products or immunoglobulin for
             the following 2 years after vaccination;

         12. Fever or suspected fever within 72 hours prior to vaccination or axillary temperature
             greater than 37,8°C on the day of vaccination (inclusion might be postponed until
             participant has completed 72 hours of no fever);

         13. Have received live virus vaccine within 28 days or killed virus vaccine in the last 14
             days prior to vaccination, or have a scheduled immunization during the first 28 days
             after receiving the investigational product;

         14. Any other condition that might put in risk the safety/rights of a potential
             participant or hurdle his/her compliance with this protocol in investigator's opinion
             or his representative physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander R Precioso, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Butantan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Butantan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esper G Kallas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander R Precioso, MD, PhD</last_name>
    <phone>+55(11)26279372</phone>
    <email>alexander.precioso@butantan.gov.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <phone>+55(11)26279372</phone>
    <email>ricardo.palacios@butantan.gov.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundação de Medicina Tropical Doutor Heitor Vieira Dourado</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Lacerda, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marcus Lacerda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Gonçalo Muniz - Fiocruz Bahia</name>
      <address>
        <city>Simões Filho</city>
        <state>BA</state>
        <zip>43700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldina Barral, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Aldina Barral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Castelo Branco Coelho, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ivo Castelo Branco Coelho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade de Brasília</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>71691-082</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30750-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Helton Santiago, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helton Santiago, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso</name>
      <address>
        <city>Cuiabá</city>
        <state>Mount</state>
        <zip>78048-610</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cor J Fontes, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Cor J Fontes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Mato Grosso do Sul</name>
      <address>
        <city>Campo Grande</city>
        <state>MS</state>
        <zip>79070-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erivaldo Elias Jr., MD</last_name>
    </contact>
    <investigator>
      <last_name>Erivaldo Elias Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Aggeu Magalhães - Fiocruz Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50740-465</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto TA Marques, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rafael Dhalia, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ernesto TA Marques, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Dhalia, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Roraima - UFRR</name>
      <address>
        <city>Boa Vista</city>
        <state>Roraima</state>
        <zip>69304-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allex J da Fonseca, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Allex J da Fonseca, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM)</name>
      <address>
        <city>Porto Velho</city>
        <state>RO</state>
        <zip>78918-791</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhelio B Pereira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dhelio B Pereira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90619-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiano Ramos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Cristina C Bonorino, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fabiano Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina C Bonorino, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sergipe</name>
      <address>
        <city>Laranjeiras</city>
        <state>SE</state>
        <zip>49170-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Q Gurgel, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Q Gurgel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de São Paulo - CSEBF</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01133-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Cássio de Moraes, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>José Cássio de Moraes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilda Salinas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de São José do Rio Preto - FAMERP</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Evandro Chagas - Fiocruz</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21710-232</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Siqueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>André Siqueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esper G Kallas, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Esper G Kallas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Precioso AR, Palacios R, Thomé B, Mondini G, Braga P, Kalil J. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. Vaccine. 2015 Dec 10;33(50):7121-5. doi: 10.1016/j.vaccine.2015.09.105. Epub 2015 Oct 14. Review.</citation>
    <PMID>26458796</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

